First line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN European retrospective study

被引：1

作者：

Asselain, B. ^{[1
]}

Martinelli, E. ^{[2
]}

Cremolini, C. ^{[3
]}

Mazard, T. ^{[4
]}

Vidal, J. ^{[5
]}

Virchow, I. ^{[6
]}

Tougeron, D. ^{[7
]}

Castagne, C. ^{[8
]}

Zkik, A. ^{[9
]}

Khan, S. ^{[10
]}

Arnold, D. ^{[11
]}

机构：

[1] ARCAGY GINECO, Stat, Paris, France

[2] Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy

[3] Azienda Osped Univ S Chiara, Polo Oncol, Pisa, Italy

[4] ICM Reg Canc Inst Montpellier, Med Oncol, Montpellier, France

[5] Hosp Del Mar IMIM, Med Oncol, Barcelona, Spain

[6] Univ Hosp Essen, West German Canc Ctr, Med Oncol, Essen, Germany

[7] CHU Poitiers, Jean Bernard Hosp, Hepatogastroenterol & Digest Oncol, Poitiers, France

[8] Pierre Fabre, Real World Evidence & Datas, Boulogne, France

[9] Pierre Fabre Oncol, Real World Evidence & Datas, Boulogne, France

[10] Pierre Fabre, Corp Med Oncol, Boulogne, France

[11] Altona Asklepios Kliniken, Asklepios Klin, Palliat Care Dept, Oncol,Haematol, Hamburg, Germany

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.959

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

438P

引用

页码：S553 / S553

页数：1